Literature DB >> 20128139

Sporadic inclusion body myositis: variability in prevalence and phenotype and influence of the MHC.

F L Mastaglia1.   

Abstract

Sporadic inclusion body myositis (sIBM) is the most common myopathy presenting over the age of 40 years but its prevalence varies considerably in different populations. Genetic factors play a part in the pathogenesis of sIBM and in Caucasians susceptibility has been linked to the HLA-DR3 allele and the 8.1 MHC ancestral haplotype (AH) which is also associated with other autoimmune diseases. The variable prevalence of sIBM in different populations may be related to differences in the population frequency of this haplotype. Our recent observations indicate that the clinical phenotype at presentation is also quite variable and that the influence of the MHC is more complex than previously appreciated with HLA alleles also having modifying effects on the age-at-onset, severity and rate of progression of the disease. Recent recombinant mapping studies of polymorphisms in the Class II/III regions of the MHC by our group have further refined the susceptibility region and have identified a number of candidate genes warranting further investigation. The significance of these findings for the pathogenesis of the disease is discussed.

Entities:  

Mesh:

Year:  2009        PMID: 20128139      PMCID: PMC2858953     

Source DB:  PubMed          Journal:  Acta Myol        ISSN: 1128-2460


  21 in total

Review 1.  Sporadic inclusion body myositis: a continuing puzzle.

Authors:  M Needham; F L Mastaglia
Journal:  Neuromuscul Disord       Date:  2007-12-21       Impact factor: 4.296

2.  Prevalence of sporadic inclusion body myositis and factors contributing to delayed diagnosis.

Authors:  Merrilee Needham; Alastair Corbett; Timothy Day; Frank Christiansen; Vicki Fabian; Frank L Mastaglia
Journal:  J Clin Neurosci       Date:  2008-09-23       Impact factor: 1.961

3.  Sporadic inclusion body myositis in Japanese is associated with the MHC ancestral haplotype 52.1.

Authors:  Adrian Phillip Scott; Richard James Nigel Allcock; Frank Mastaglia; Ichizo Nishino; Ikuya Nonaka; Nigel Laing
Journal:  Neuromuscul Disord       Date:  2006-03-24       Impact factor: 4.296

Review 4.  Inclusion body myositis and myopathies.

Authors:  R C Griggs; V Askanas; S DiMauro; A Engel; G Karpati; J R Mendell; L P Rowland
Journal:  Ann Neurol       Date:  1995-11       Impact factor: 10.422

5.  Immunogenetic risk and protective factors for the idiopathic inflammatory myopathies: distinct HLA-A, -B, -Cw, -DRB1 and -DQA1 allelic profiles and motifs define clinicopathologic groups in caucasians.

Authors:  Terrance P O'Hanlon; Danielle Mercatante Carrick; Frank C Arnett; John D Reveille; Mary Carrington; Xiaojiang Gao; Chester V Oddis; Penelope A Morel; James D Malley; Karen Malley; Jonathan Dreyfuss; Ejaz A Shamim; Lisa G Rider; Stephen J Chanock; Charles B Foster; Thomas Bunch; Paul H Plotz; Lori A Love; Frederick W Miller
Journal:  Medicine (Baltimore)       Date:  2005-11       Impact factor: 1.889

6.  Proposed immunologic models of the inflammatory myopathies and potential therapeutic implications.

Authors:  Steven A Greenberg
Journal:  Neurology       Date:  2007-10-10       Impact factor: 9.910

Review 7.  Genetics of inclusion-body myositis.

Authors:  M Needham; F L Mastaglia; M J Garlepp
Journal:  Muscle Nerve       Date:  2007-05       Impact factor: 3.217

8.  Study of idiopathic inflammatory myopathies with special reference to borderland between idiopathic inflammatory myopathies and muscular dystrophies.

Authors:  Satish V Khadilkar; Shekhar G Patil; Sanjeev N Amin
Journal:  Neurol India       Date:  2008 Jul-Sep       Impact factor: 2.117

9.  Sporadic inclusion body myositis: phenotypic variability and influence of HLA-DR3 in a cohort of 57 Australian cases.

Authors:  M Needham; I James; A Corbett; T Day; F Christiansen; B Phillips; F L Mastaglia
Journal:  J Neurol Neurosurg Psychiatry       Date:  2008-02-07       Impact factor: 10.154

10.  Sporadic-inclusion body myositis (s-IBM) is not so prevalent in Istanbul/Turkey: a muscle biopsy based survey.

Authors:  P Serdaroglu Oflazer; F Deymeer; Y Parman
Journal:  Acta Myol       Date:  2011-06
View more
  9 in total

Review 1.  The Clinical and Histological Spectrum of Idiopathic Inflammatory Myopathies.

Authors:  Ilaria Cavazzana; Micaela Fredi; Carlo Selmi; Angela Tincani; Franco Franceschini
Journal:  Clin Rev Allergy Immunol       Date:  2017-02       Impact factor: 8.667

Review 2.  New Developments in the Genetics of Inclusion Body Myositis.

Authors:  Kyla A Britson; Stephanie Y Yang; Thomas E Lloyd
Journal:  Curr Rheumatol Rep       Date:  2018-04-02       Impact factor: 4.592

Review 3.  Idiopathic Inflammatory Myopathies: an Update on Classification and Treatment with Special Focus on Juvenile Forms.

Authors:  Ilaria Pagnini; Antonio Vitale; Carlo Selmi; Rolando Cimaz; Luca Cantarini
Journal:  Clin Rev Allergy Immunol       Date:  2017-02       Impact factor: 10.817

4.  Sporadic-inclusion body myositis (s-IBM) is not so prevalent in Istanbul/Turkey: a muscle biopsy based survey.

Authors:  P Serdaroglu Oflazer; F Deymeer; Y Parman
Journal:  Acta Myol       Date:  2011-06

5.  Development and evaluation of a standardized ELISA for the determination of autoantibodies against cN-1A (Mup44, NT5C1A) in sporadic inclusion body myositis.

Authors:  Sabine L Kramp; Dmitry Karayev; Guo Shen; Allan L Metzger; Robert I Morris; Eugene Karayev; Yvonne Lam; Richard M Kazdan; Ger J M Pruijn; Sandra Saschenbrecker; Cornelia Dähnrich; Wolfgang Schlumberger
Journal:  Auto Immun Highlights       Date:  2016-11-17

Review 6.  Inclusion body myositis - pathomechanism and lessons from genetics.

Authors:  Balázs Murnyák; Levente Bodoki; Melinda Vincze; Zoltán Griger; Tamás Csonka; Rita Szepesi; Andrea Kurucz; Katalin Dankó; Tibor Hortobágyi
Journal:  Open Med (Wars)       Date:  2015-02-26

7.  Mortality and Causes of Death in Patients with Sporadic Inclusion Body Myositis: Survey Study Based on the Clinical Experience of Specialists in Australia, Europe and the USA.

Authors:  Mark A Price; Victoria Barghout; Olivier Benveniste; Lisa Christopher-Stine; Alastair Corbett; Marianne de Visser; David Hilton-Jones; John T Kissel; Thomas E Lloyd; Ingrid E Lundberg; Francis Mastaglia; Tahseen Mozaffar; Merrilee Needham; Jens Schmidt; Kumaraswamy Sivakumar; Carla DeMuro; Brian S Tseng
Journal:  J Neuromuscul Dis       Date:  2016-03-03

Review 8.  Immune and myodegenerative pathomechanisms in inclusion body myositis.

Authors:  Christian W Keller; Jens Schmidt; Jan D Lünemann
Journal:  Ann Clin Transl Neurol       Date:  2017-05-16       Impact factor: 4.511

Review 9.  Emerging therapeutic options for sporadic inclusion body myositis.

Authors:  Lindsay N Alfano; Linda P Lowes
Journal:  Ther Clin Risk Manag       Date:  2015-09-25       Impact factor: 2.423

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.